Depersonalisation disorder is characterised Depersonalisation disorder is characterised by a subjective sense of unreality and by a subjective sense of unreality and detachment from the self (Simeon detachment from the self (Simeon et al et al, , 1997 (Simeon et al et al, , , 2003 Baker 1997 Baker , 2003 Baker et al et al, 2003) . The dis-, 2003) . The disorder is diagnosed when depersonalisation order is diagnosed when depersonalisation is persistent or recurrent, causes marked is persistent or recurrent, causes marked distress or impairment, and is not part of distress or impairment, and is not part of another psychiatric or medical condition. another psychiatric or medical condition. The illness is often chronic and debilitating, The illness is often chronic and debilitating, and there is no known pharmacotherapy and there is no known pharmacotherapy (Simeon, 2004) . A small controlled trial (Simeon, 2004) . A small controlled trial found no efficacy for lamotrigine (Sierra found no efficacy for lamotrigine (Sierra et al et al, 2003) . Over the past decade there , 2003) . Over the past decade there have been anecdotal reports of improvehave been anecdotal reports of improvement in depersonalisation with selective ment in depersonalisation with selective serotonin reuptake inhibitors (Hollander serotonin reuptake inhibitors (Hollander et al et al, 1990; Fichtner , 1990; Fichtner et al et al, 1992; Ratliff & , 1992; Ratliff & Kerski, 1995) or clomipramine (Simeon Kerski, 1995) or clomipramine (Simeon et et al al, 1998 , 1998a a). The aim of our study was to ). The aim of our study was to evaluate systematically the efficacy of evaluate systematically the efficacy of fluoxetine in a randomised, doublefluoxetine in a randomised, doublemasked, placebo-controlled trial. We premasked, placebo-controlled trial. We predicted that fluoxetine would be superior dicted that fluoxetine would be superior to placebo, and that improvement in deto placebo, and that improvement in depersonalisation would be independent of personalisation would be independent of psychiatric comorbidity. psychiatric comorbidity.
METHOD METHOD Participants Participants
People eligible for the study were adults People eligible for the study were adults aged 18-65 years, who met DSM-IV diagaged 18-65 years, who met DSM-IV diagnostic criteria for current depersonalisation nostic criteria for current depersonalisation disorder by semi-structured clinical interdisorder by semi-structured clinical interview and by the Structured Clinical Interview and by the Structured Clinical Interview for DSM-IV Dissociative Disorders view for DSM-IV Dissociative Disorders (Steinberg, 1994) . The DSM-IV criteria (Steinberg, 1994) . The DSM-IV criteria are essentially the same as the ICD-10 criare essentially the same as the ICD-10 criteria (World Health Organization, 1992) , teria (World Health Organization, 1992) , and postulate persistent depersonalisation, and postulate persistent depersonalisation, with intact reality testing, not occurring with intact reality testing, not occurring exclusively in the context of another diagexclusively in the context of another diagnosable disorder (American Psychiatric nosable disorder (American Psychiatric Association, 1994) . Participants were selfAssociation, 1994). Participants were selfreferred by responding to newspaper adverreferred by responding to newspaper advertisements for research ('do you frequently tisements for research ('do you frequently feel unreal/detached, as if in a dream/ feel unreal/detached, as if in a dream/ fog?'). After a telephone screening, potenfog?'). After a telephone screening, potentially suitable individuals were seen for an tially suitable individuals were seen for an initial clinical evaluation. For inclusion in initial clinical evaluation. For inclusion in the study, individuals had to have taken the study, individuals had to have taken no psychotropic medication for a period no psychotropic medication for a period of at least 2 weeks (4 weeks for monoamine of at least 2 weeks (4 weeks for monoamine oxidase inhibitors or investigational drugs). oxidase inhibitors or investigational drugs). Applicants were not eligible if they had Applicants were not eligible if they had previously undergone an adequate fluoxpreviously undergone an adequate fluoxetine trial, defined as a minimum of 10 mg etine trial, defined as a minimum of 10 mg daily for 4 weeks, or if they reported fluoxdaily for 4 weeks, or if they reported fluoxetine intolerance or hypersensitivity. Writetine intolerance or hypersensitivity. Written informed consent was obtained after a ten informed consent was obtained after a full explanation of the study by the princifull explanation of the study by the principal investigator. About one participant pal investigator. About one participant was enrolled for every 15 people who was enrolled for every 15 people who were screened. There was no payment for were screened. There was no payment for participation in the research. participation in the research.
People with lifetime diagnoses of People with lifetime diagnoses of schizophrenia, schizoaffective disorder, schizophrenia, schizoaffective disorder, bipolar disorder or organic mental disorder bipolar disorder or organic mental disorder were excluded from the study, as were indiwere excluded from the study, as were individuals with current substance use disorder viduals with current substance use disorder or eating disorder. Lifetime Axis I disorders or eating disorder. Lifetime Axis I disorders were assessed using the Structured Clinical were assessed using the Structured Clinical Interview for DSM-IV Axis I Disorders Interview for DSM-IV Axis I Disorders (First (First et al et al, 1995) , and Axis II personality , 1995), and Axis II personality disorders were assessed with the Structured disorders were assessed with the Structured Interview for DSM-IV Personality DisInterview for DSM-IV Personality Disorders (Pfohl orders (Pfohl et al et al, 1995) . Participants were , 1995). Participants were allowed to enter the trial if they had been allowed to enter the trial if they had been receiving psychotherapy for at least 3 receiving psychotherapy for at least 3 months, but those who had recently begun months, but those who had recently begun psychotherapy or were receiving specialised psychotherapy or were receiving specialised treatment such as cognitive-behavioural treatment such as cognitive-behavioural therapy and hypnosis were excluded. Inditherapy and hypnosis were excluded. Individuals with acute or unstable medical illviduals with acute or unstable medical illnesses, as well as those with a history of nesses, as well as those with a history of seizure disorder or major head trauma, seizure disorder or major head trauma, were also excluded. All participants had a were also excluded. All participants had a normal baseline routine laboratory evaluanormal baseline routine laboratory evaluation with negative urine toxicology screention with negative urine toxicology screenings. Women of childbearing age were ings. Women of childbearing age were required to use an effective birth control required to use an effective birth control method; pregnant and lactating women method; pregnant and lactating women were excluded. were excluded.
Design Design
The study was a double-masked, randomThe study was a double-masked, randomised, parallel, flexible-dosage comparison ised, parallel, flexible-dosage comparison of fluoxetine of fluoxetine v.
v. placebo for the treatment placebo for the treatment of depersonalisation disorder. After a 2-of depersonalisation disorder. After a 2-week single-masked placebo run-in phase, week single-masked placebo run-in phase, participants were randomised to receive participants were randomised to receive identical-appearing fluoxetine or placebo identical-appearing fluoxetine or placebo capsules. Participants were assigned to the capsules. Participants were assigned to the fluoxetine or placebo group by the institufluoxetine or placebo group by the institution's pharmacy on the basis of a standard tion's pharmacy on the basis of a standard randomisation table, unknown to the randomisation table, unknown to the 
B R I T I S H J O UR N A L O F P SYC HI AT RY B R I T I S H J O UR N A L O F P S YC H I AT RY
( 2 0 0 4 ) , 1 8 5 , 31^3 6 ( 2 0 0 4 ) , 1 8 5
Measures Measures
The same measures were administered at The same measures were administered at each treatment visit. Three primary outeach treatment visit. Three primary outcome measures were used, in order to give come measures were used, in order to give a comprehensive picture of patient-rated a comprehensive picture of patient-rated symptoms, clinician-rated symptoms and symptoms, clinician-rated symptoms and an overall clinical impression. an overall clinical impression.
Clinical Global Impression Clinical Global Impression
The Clinical Global Impression scale (CGI; The Clinical Global Impression scale (CGI; Guy, 1976 ) is a standard clinician-rated, Guy, 1976 ) is a standard clinician-rated, seven-point scale; the severity scale (CGI-S) seven-point scale; the severity scale (CGI-S) was applied at the initial visit, and the was applied at the initial visit, and the improvement scale (CGI-I) was applied improvement scale (CGI-I) was applied during all subsequent visits, specifically to during all subsequent visits, specifically to rate change in depersonalisation. rate change in depersonalisation.
Dissociative Experiences Scale Dissociative Experiences Scale
The Dissociative Experiences Scale (DES; The Dissociative Experiences Scale (DES; Bernstein-Carlson & Putnam, 1993) is by Bernstein-Carlson & Putnam, 1993) is by far the most widely applied measure of disfar the most widely applied measure of dissociation, having been used in over 250 sociation, having been used in over 250 research studies to date. It is a 28-item research studies to date. It is a 28-item self-report questionnaire of dissociative self-report questionnaire of dissociative experiences: each item is scored at 10% experiences: each item is scored at 10% intervals from 0% to 100%, and the total intervals from 0% to 100%, and the total score is the mean of all items. The DES score is the mean of all items. The DES has been shown to have good test-retest has been shown to have good test-retest reliability (intraclass correlation coefficient reliability (intraclass correlation coefficient 0.79-0.96), high internal consistency 0.79-0.96), high internal consistency (Cronbach's (Cronbach's a a¼0.95) and strong conver-0.95) and strong convergent, discriminant and criterion validity. gent, discriminant and criterion validity. The DES has also been used as a state The DES has also been used as a state measure in treatment settings, where measure in treatment settings, where patients are asked to rate their experience patients are asked to rate their experience in the past week only; in this context it in the past week only; in this context it has been shown to be sensitive to treatment has been shown to be sensitive to treatment change (Ellason & Ross, 1997; Lubin change (Ellason & Ross, 1997; Lubin et al et al, , 1998; Simeon 1998; Simeon et al et al, 2001) . Furthermore, , 2001 ). Furthermore, factor analysis of the DES in people with factor analysis of the DES in people with depersonalisation disorder has yielded depersonalisation disorder has yielded three factors -absorption, amnesia and dethree factors -absorption, amnesia and depersonalisation/derealisation (Simeon personalisation/derealisation (Simeon et et al al, 1998 , 1998b b) -and in our study we use a ) -and in our study we use a depersonalisation score (DES-DP) based depersonalisation score (DES-DP) based on the particular factor analysis (mean of on the particular factor analysis (mean of DES items 7, 12, 13, 24 and 28). DES items 7, 12, 13, 24 and 28).
Depersonalization Severity Scale Depersonalization Severity Scale
The Depersonalization Severity Scale (DSS; The Depersonalization Severity Scale (DSS;
) is a six-item, clinicianadministered scale of depersonalisation administered scale of depersonalisation experiences rated 0-3, applied to the past experiences rated 0-3, applied to the past week, which takes into account both sympweek, which takes into account both symptom frequency and intensity. It has been tom frequency and intensity. It has been found to have excellent interrater reliabilfound to have excellent interrater reliability, moderate internal consistency, high ity, moderate internal consistency, high convergent and divergent validity, and to convergent and divergent validity, and to be sensitive to treatment change (Simeon be sensitive to treatment change (Simeon et al et al, 2001) .
, 2001).
Secondary outcome measures Secondary outcome measures
The following secondary outcome measures The following secondary outcome measures were clinician-administered at each visit. were clinician-administered at each visit. Depression was measured using the 17-item Depression was measured using the 17-item Hamilton Rating Scale , 1999) , a 25-item scale measuring both 1999), a 25-item scale measuring both social anxiety and consequent avoidance. social anxiety and consequent avoidance. Obsessive-compulsive symptoms were Obsessive-compulsive symptoms were measured using the Yale-Brown Obsessive measured using the Yale-Brown Obsessive Compulsive Severity scale (Goodman Compulsive Severity scale (Goodman et et al al, 1989) , a ten-item scale that measures , 1989), a ten-item scale that measures obsessions and compulsions The Panic obsessions and compulsions The Panic Attack Diary was a weekly subject-generated Attack Diary was a weekly subject-generated record of total number of panic attacks. In record of total number of panic attacks. In addition to these scales, CGI-I scores were addition to these scales, CGI-I scores were applied to all existent comorbid disorders applied to all existent comorbid disorders to measure treatment change in each. to measure treatment change in each.
Statistical analyses Statistical analyses
An intention-to-treat analysis was perAn intention-to-treat analysis was performed, with last observation carried forformed, with last observation carried forward for participants who did not ward for participants who did not complete the trial. For each of the three complete the trial. For each of the three primary outcome measures, two types of primary outcome measures, two types of analyses of covariance (ANCOVAs) were analyses of covariance (ANCOVAs) were performed, one not controlling and the performed, one not controlling and the other controlling for depression and anxiety other controlling for depression and anxiety variables. In the former ANCOVAs, variables. In the former ANCOVAs, baseline scores were used as the only cobaseline scores were used as the only covariate. The latter ANCOVAs included six variate. The latter ANCOVAs included six additional covariates in order to control additional covariates in order to control for baseline and treatment effects in anxifor baseline and treatment effects in anxiety, depression and social anxiety, using ety, depression and social anxiety, using baseline HRSD, HRSA and LSAS scores, baseline HRSD, HRSA and LSAS scores, as well as change scores in these variables as well as change scores in these variables between baseline and week 10. Obsessivebetween baseline and week 10. Obsessivecompulsive and panic attack symptom compulsive and panic attack symptom scores were not included in the latter scores were not included in the latter analyses because they were minimal (see analyses because they were minimal (see Table 3 ). Specifically for the CGI-I ana- Table 3 ). Specifically for the CGI-I analyses, the baseline CGI-S score was used lyses, the baseline CGI-S score was used as the covariate, and for the four people as the covariate, and for the four people who did not reach the week 2 treatment who did not reach the week 2 treatment visit, a CGI-I score of 4 was assumed. For visit, a CGI-I score of 4 was assumed. For two treatment groups, each consisting of two treatment groups, each consisting of 25 participants, to achieve a power of 25 participants, to achieve a power of 0.80 in detecting group differences with a 0.80 in detecting group differences with a two-tailed test at the 0.5 level of signifitwo-tailed test at the 0.5 level of significance, the effect size (difference between cance, the effect size (difference between means divided by the common standard means divided by the common standard deviation) would have to be 0.81 (Cohen, deviation) would have to be 0.81 (Cohen, 1988 (Cohen, ). 1988 .
A categorical analysis of responders A categorical analysis of responders v. v. non-responders was conducted using a non-responders was conducted using a w w 2 2 test, defined as a CGI-I score of 2 or 1, test, defined as a CGI-I score of 2 or 1, combined with a decrease of at least 30% combined with a decrease of at least 30% in the two depersonalisation symptom in the two depersonalisation symptom measures. Chi-squared tests were also used measures. Chi-squared tests were also used to compare demographic and clinical charto compare demographic and clinical characteristics of the two groups where approacteristics of the two groups where appropriate, as well as categorical treatment priate, as well as categorical treatment response in relation to the presence of Axis response in relation to the presence of Axis I or Axis II disorders. For all 2 I or Axis II disorders. For all 26 62 2 w w 2 2 tests tests with an expected value of less than 5 in with an expected value of less than 5 in any cell, continuity correction was any cell, continuity correction was employed. Independent sample Student's employed. Independent sample Student's t t-tests were used to compare demographic -tests were used to compare demographic and illness variables between the two and illness variables between the two groups where appropriate. All statistics groups where appropriate. All statistics are two-tailed with a 0.5 level of are two-tailed with a 0.5 level of significance. significance.
RESULTS RESULTS

Sample characteristics Sample characteristics
Fifty-four people entered the placebo run-in Fifty-four people entered the placebo run-in period, of whom four were not randomised: period, of whom four were not randomised: two of them did not return for the subtwo of them did not return for the subsequent visit, one experienced a complete sequent visit, one experienced a complete resolution of depersonalisation symptoms, resolution of depersonalisation symptoms, and one experienced severe adverse effects and one experienced severe adverse effects on placebo. Of the 50 participants randomon placebo. Of the 50 participants randomised, 25 to fluoxetine and 25 to placebo, ised, 25 to fluoxetine and 25 to placebo, three-quarters (37) completed the trial, 16 three-quarters (37) completed the trial, 16 on fluoxetine and 21 on placebo. The on fluoxetine and 21 on placebo. The withdrawal rate in the two treatment withdrawal rate in the two treatment groups did not significantly differ groups did not significantly differ ( (w w 2 2 ¼2.60, d.f.
2.60, d.f.¼1, 1, P P¼0.11). The mean daily 0.11). The mean daily dose reached in the study was 48 mg for dose reached in the study was 48 mg for fluoxetine and 46 mg for placebo ( fluoxetine and 46 mg for placebo (t t¼0.45, 0.45, d.f. d.f.¼48, 48, P P¼0.65). 0.65). People withdrawing from the fluoxetine People withdrawing from the fluoxetine group were individually accounted for as group were individually accounted for as follows: two persons before week 2, one follows: two persons before week 2, one to seek private treatment and one with worto seek private treatment and one with worsening anxiety; three persons before week sening anxiety; three persons before week 4, one to attempt impregnation (CGI-I 5), 4, one to attempt impregnation (CGI-I 5), one to seek private treatment (CGI-I 4) one to seek private treatment (CGI-I 4) and one discontinued by the investigators and one discontinued by the investigators for worsening depression (CGI-I 3); two for worsening depression (CGI-I 3); two persons did not return (without explanapersons did not return (without explanation) before week 8 (CGI-I 2 and 4); and tion) before week 8 (CGI-I 2 and 4); and two persons dropped out before the final two persons dropped out before the final visit, one who relocated (CGI-I 5) and visit, one who relocated (CGI-I 5) and one who did not return, without explanaone who did not return, without explanation (CGI-I 1). Withdrawals from the plation (CGI-I 1). Withdrawals from the placebo group were individually accounted cebo group were individually accounted for as follows: two persons before week 2, for as follows: two persons before week 2, one because of work schedule and one one because of work schedule and one without an explanation; and two persons without an explanation; and two persons by week 4, one because of work schedule by week 4, one because of work schedule (CGI-I 4) and one non-compliant with (CGI-I 4) and one non-compliant with treatment visits (CGI-I 4). treatment visits (CGI-I 4).
The demographic and illness characterThe demographic and illness characteristics of the 50 participants with DSM-IV istics of the 50 participants with DSM-IV depersonalisation disorder who composed depersonalisation disorder who composed the intention-to-treat sample are given in the intention-to-treat sample are given in Table 1 . Current comorbidity is sum- Table 1 . Current comorbidity is summarised in Table 2 . It can be seen that the marised in Table 2 . It can be seen that the two study groups did not differ on any two study groups did not differ on any demographic or clinical variables. There demographic or clinical variables. There was a trend toward more people with was a trend toward more people with depressive disorders in the fluoxetine group depressive disorders in the fluoxetine group and more people with anxiety disorders in and more people with anxiety disorders in the placebo group, which did not reach the placebo group, which did not reach statistical significance. statistical significance.
Treatment outcome Treatment outcome
The six ANCOVA analyses of the three The six ANCOVA analyses of the three primary outcome variables revealed that primary outcome variables revealed that fluoxetine was not superior to placebo in fluoxetine was not superior to placebo in treating depersonalisation, with the exceptreating depersonalisation, with the exception of a statistically significant improvetion of a statistically significant improvement in CGI-I score when not covaried ment in CGI-I score when not covaried for depression and anxiety (Table 3 ). The for depression and anxiety (Table 3 ). The mean improvement in CGI score with mean improvement in CGI score with fluoxetine was clinically modest (2.9), fluoxetine was clinically modest (2.9), although statistically greater than the plaalthough statistically greater than the placebo mean improvement of 3.6. Bi-weekly cebo mean improvement of 3.6. Bi-weekly changes in the three primary outcome changes in the three primary outcome measures are shown in Fig. 1 . Finally, a measures are shown in Fig. 1 . Finally, a categorical analysis of responder status recategorical analysis of responder status revealed a 24% response rate on fluoxetine vealed a 24% response rate on fluoxetine ( (n n¼6) and a 20% response rate on placebo 6) and a 20% response rate on placebo ( (n n¼5) ( 5) (w w 2 2 ¼0.12, d.f. 0.12, d.f.¼1, 1, P P¼0.73). 0.73). Baseline anxiety and depression scores Baseline anxiety and depression scores were modest (Table 3) , probably accountwere modest (Table 3) , probably accounting for the absence of a differential ing for the absence of a differential improvement in anxious and depressive improvement in anxious and depressive symptoms during treatment between the symptoms during treatment between the two groups as a whole. However, if the partwo groups as a whole. However, if the participants who had a diagnosis of depressive ticipants who had a diagnosis of depressive or anxiety disorder are considered alone or anxiety disorder are considered alone (Table 2) , those taking fluoxetine consis- (Table 2) , those taking fluoxetine consistently tended to have better responses than tently tended to have better responses than those taking the placebo, as defined by those taking the placebo, as defined by CGI-I scores of 2 or 1 for the particular dis-CGI-I scores of 2 or 1 for the particular disorder: 50% order: 50% v.
v. 0% for major depression, 0% for major depression, 75% 75% v.
v. 25% for dysthymia, 50% 25% for dysthymia, 50% v. v. 40% 40% for generalised anxiety disorder, 100% for generalised anxiety disorder, 100% v.
v. 25% for obsessive-compulsive disorder, 25% for obsessive-compulsive disorder, 50% 50% v.
v. 40% for panic disorder and 33% 40% for panic disorder and 33% v. v. 13% for social phobia.
13% for social phobia. Finally, we specifically examined the Finally, we specifically examined the depersonalisation disorder CGI-I score in depersonalisation disorder CGI-I score in relation to comorbidity, as this was the relation to comorbidity, as this was the only primary outcome variable to show difonly primary outcome variable to show differential improvement on fluoxetine, prior ferential improvement on fluoxetine, prior to covarying for anxiety and depression. to covarying for anxiety and depression. For the fluoxetine group, end-point CGI-I For the fluoxetine group, end-point CGI-I score for depersonalisation disorder did score for depersonalisation disorder did not significantly differ according to the prenot significantly differ according to the presence or absence of clinical improvement sence or absence of clinical improvement (CGI-I) in comorbid depressive disorders (CGI-I) in comorbid depressive disorders ( (w w the nine persons in the fluoxetine group the nine persons in the fluoxetine group who did have comorbid anxiety disorder, who did have comorbid anxiety disorder, the four who were anxiety disorder the four who were anxiety disorder responders were all depersonalisation disresponders were all depersonalisation disorder responders by CGI-I. Of the five order responders by CGI-I. Of the five whose anxiety disorder did not respond to whose anxiety disorder did not respond to fluoxetine, only one was a depersonalisafluoxetine, only one was a depersonalisation disorder responder. Finally, within tion disorder responder. Finally, within the fluoxetine group, depersonalisation the fluoxetine group, depersonalisation responder status did not significantly differ responder status did not significantly differ in the presence or absence of personality in the presence or absence of personality disorder ( disorder (w w 2 2 ¼0.00, d.f. 0.00, d.f.¼1, 1, P P¼1.00). 1.00).
Adverse events Adverse events
Side-effects occurring at a frequency of at Side-effects occurring at a frequency of at least 10% in at least one of the two study least 10% in at least one of the two study groups included decreased appetite (36% groups included decreased appetite (36% fluoxetine, 4% placebo), muscle stiffness fluoxetine, 4% placebo), muscle stiffness or cramping (16% fluoxetine, 12% or cramping (16% fluoxetine, 12% placebo), tremor (16% fluoxetine, 0% placebo), tremor (16% fluoxetine, 0% placebo), nervousness (28% fluoxetine, placebo), nervousness (28% fluoxetine, 40% placebo), excitation or hyperactivity 40% placebo), excitation or hyperactivity (8% fluoxetine, 12% placebo), fatigue (8% fluoxetine, 12% placebo), fatigue (48% fluoxetine, 16% placebo), sedation (48% fluoxetine, 16% placebo), sedation (20% fluoxetine, 0% placebo), headaches (20% fluoxetine, 0% placebo), headaches (28% both groups), diarrhoea (16% both (28% both groups), diarrhoea (16% both groups), nausea (40% fluoxetine, 20% groups), nausea (40% fluoxetine, 20% placebo), stomach ache (12% both groups), placebo), stomach ache (12% both groups), urinary frequency (20% fluoxetine, 8% urinary frequency (20% fluoxetine, 8% placebo), palpitations (4% fluoxetine, placebo), palpitations (4% fluoxetine, 20% placebo), dizziness/lightheadedness 20% placebo), dizziness/lightheadedness (16% both groups), blurry vision (12% (16% both groups), blurry vision (12% fluoxetine, 8% placebo), sweating (16% fluoxetine, 8% placebo), sweating (16% fluoxetine, 12% placebo), insomnia (48% fluoxetine, 12% placebo), insomnia (48% fluoxetine, 24% placebo), decreased libido fluoxetine, 24% placebo), decreased libido (48% fluoxetine, 20% placebo) and de-(48% fluoxetine, 20% placebo) and decreased sexual arousal (24% fluoxetine, creased sexual arousal (24% fluoxetine, 4% placebo). Only one person from the 4% placebo). Only one person from the fluoxetine group discontinued the trial prefluoxetine group discontinued the trial prematurely because of adverse effects, in this maturely because of adverse effects, in this case heightened anxiety. Therefore, to our case heightened anxiety. Therefore, to our knowledge, the greater withdrawal rate in knowledge, the greater withdrawal rate in the medication arm was not due to adverse the medication arm was not due to adverse events. events.
DISCUSSION DISCUSSION
Lack of efficacy of fluoxetine Lack of efficacy of fluoxetine for primary depersonalisation for primary depersonalisation
This first controlled study of serotonin This first controlled study of serotonin reuptake inhibitor treatment for primary reuptake inhibitor treatment for primary depersonalisation failed to support the depersonalisation failed to support the possible efficacy suggested by earlier anecpossible efficacy suggested by earlier anecdotal data. Previous reports had found that dotal data. Previous reports had found that improvement in depersonalisation was cloimprovement in depersonalisation was closely related to the presence of other sympsely related to the presence of other symptoms responsive to serotonin reuptake toms responsive to serotonin reuptake inhibitors, such as panic or obsessions inhibitors, such as panic or obsessions (Hollander (Hollander et al et al, 1990) ; furthermore, retro-, 1990); furthermore, retrospective treatment reviews in depersonalisaspective treatment reviews in depersonalisation disorder had reported only modest tion disorder had reported only modest efficacy for serotonin reuptake inhibitor efficacy for serotonin reuptake inhibitor therapy (Simeon therapy (Simeon et al et al, 1997 (Simeon et al et al, , 2003 . , 1997, 2003) . Both clinician-rated and self-rated disBoth clinician-rated and self-rated dissociation scores showed a modest decline sociation scores showed a modest decline in both treatment groups, which was cliniin both treatment groups, which was clinically not noteworthy and statistically no cally not noteworthy and statistically no different. The statistically significant different. The statistically significant improvement in depersonalisation by improvement in depersonalisation by CGI-I score in the fluoxetine group, before CGI-I score in the fluoxetine group, before correction for depression and anxiety correction for depression and anxiety effects, was also not clinically significant, effects, was also not clinically significant, as the average improvement score was as the average improvement score was approximately 3, i.e. minimal change. approximately 3, i.e. minimal change. Indeed, a number of the participants who Indeed, a number of the participants who experienced some improvement on fluoxeexperienced some improvement on fluoxetine expressed this effect in words, stating tine expressed this effect in words, stating that their symptoms had not really that their symptoms had not really changed, but that they seemed somehow changed, but that they seemed somehow to take less notice or be less bothered by to take less notice or be less bothered by them. The study finding of slight improvethem. The study finding of slight improvement in CGI-I score without notable ment in CGI-I score without notable improvement in depersonalisation sympimprovement in depersonalisation symptom ratings on fluoxetine mirrors these tom ratings on fluoxetine mirrors these subjective experiences. subjective experiences.
Comorbidity and treatment Comorbidity and treatment outcome outcome
It is possible that some alleviation of coIt is possible that some alleviation of comorbid anxiety and depression contributed morbid anxiety and depression contributed to an overall more tolerable affective state, to an overall more tolerable affective state, which led participants to experience their which led participants to experience their depersonalisation as less troubling although depersonalisation as less troubling although essentially unchanged. Indeed, a mediating essentially unchanged. Indeed, a mediating 3 4 3 4 effect of comorbid anxiety and depression effect of comorbid anxiety and depression is suggested by the loss of statistically is suggested by the loss of statistically significant improvement in CGI-I when significant improvement in CGI-I when covaried for baseline and change in anxiety covaried for baseline and change in anxiety and depression, as well as by the greater and depression, as well as by the greater improvement in anxiety disorders in those improvement in anxiety disorders in those whose depersonalisation responded to whose depersonalisation responded to fluoxetine, compared with non-responders. fluoxetine, compared with non-responders.
The relationship of depersonalisation to The relationship of depersonalisation to anxiety and depression has been debated anxiety and depression has been debated for decades, and it would be fair to say that for decades, and it would be fair to say that the issue remains controversial. Earlier the issue remains controversial. Earlier investigators eloquently described the investigators eloquently described the relationship of depersonalisation to phobic relationship of depersonalisation to phobic anxiety (Roth, 1959) , depression (Sedman, anxiety (Roth, 1959 ), depression (Sedman, 1972 and obsessions (Torch, 1978) . More 1972) and obsessions (Torch, 1978) . More recently, David and colleagues have recently, David and colleagues have favoured the view that depersonalisation favoured the view that depersonalisation disorder should be placed with the mood disorder should be placed with the mood and anxiety disorders (Baker and anxiety disorders (Baker et al et al, 2003) . , 2003 ). An alternative view, however, is that An alternative view, however, is that extreme emotional states such as severe extreme emotional states such as severe depression or anxiety are one type of 'traudepression or anxiety are one type of 'traumatic stress', among many others, that may matic stress', among many others, that may trigger depersonalisation in individuals trigger depersonalisation in individuals with an underlying vulnerability; in some with an underlying vulnerability; in some cases, the depersonalisation may become cases, the depersonalisation may become chronic and autonomous of the precipitatchronic and autonomous of the precipitating stressor (Simeon ing stressor (Simeon et al et al, 2003) . The lack , 2003) . The lack of responsiveness of depersonalisation to of responsiveness of depersonalisation to fluoxetine supports the latter concept, that fluoxetine supports the latter concept, that depersonalisation disorder is a distinct disdepersonalisation disorder is a distinct dissociative disorder. Indeed, as long ago as sociative disorder. Indeed, as long ago as the 1930s Mayer-Gross (1935) conceptualthe 1930s Mayer-Gross (1935) conceptualised depersonalisation as a universal preised depersonalisation as a universal preformed functional response of the brain to formed functional response of the brain to extreme stress. extreme stress.
Strengths and limitations
Strengths and limitations of the study of the study Strengths of the study include the fluoxetine Strengths of the study include the fluoxetine dosing and the trial duration; the use of dosing and the trial duration; the use of well-validated dissociation measures, both well-validated dissociation measures, both clinician-rated and self-reported; the use clinician-rated and self-reported; the use of an independent evaluator masked to of an independent evaluator masked to adverse events and medication adjustment adverse events and medication adjustment to conduct the clinical ratings; and the to conduct the clinical ratings; and the stringent selection criteria for the particistringent selection criteria for the participants with primary DSM-IV depersonalisapants with primary DSM-IV depersonalisation disorder. Limitations include the tion disorder. Limitations include the higher withdrawal rate in the fluoxetine higher withdrawal rate in the fluoxetine arm, and the medium size of the sample. arm, and the medium size of the sample.
Implications for treatment Implications for treatment
Our study suggests that first-line use of Our study suggests that first-line use of serotonin reuptake inhibitors for the treatserotonin reuptake inhibitors for the treatment of depersonalisation disorder is not ment of depersonalisation disorder is not indicated, except possibly in selected indiindicated, except possibly in selected individuals with troublesome anxiety or depresviduals with troublesome anxiety or depression; in such individuals, improved affective sion; in such individuals, improved affective state might result in a somewhat better state might result in a somewhat better tolerance of their dissociative symptoms. tolerance of their dissociative symptoms. Although negative, the findings of this Although negative, the findings of this study are important in light of the absence study are important in light of the absence of any efficacious pharmacotherapy for of any efficacious pharmacotherapy for 3 5 3 5 1. For each primary variable, the first analysis of covariance has one covariate (baseline score) and the second has six additional covariates (baseline and change in HRSD, HRSA and 1. For each primary variable, the first analysis of covariance has one covariate (baseline score) and the second has six additional covariates (baseline and change in HRSD, HRSA and LSAS). LSAS). The unresponsiveness of depersonalisation to fluoxetine supports the concept that depersonalisation disorder is a dissociative rather than a depression/anxiety that depersonalisation disorder is a dissociative rather than a depression/anxiety spectrum disorder. spectrum disorder.
LIMITATIONS LIMITATIONS
& & The sample size was modest.
The sample size was modest.
& & There was a higher withdrawal rate in the fluoxetine group. There was a higher withdrawal rate in the fluoxetine group.
& & Many of the participants also had depressive and anxiety disorders. Many of the participants also had depressive and anxiety disorders.
